Incyte and Syndax Announce U.S. Food and Drug Administration Approval of Niktimvo 9 mg and 22 mg Vial Sizes
SNDX Stock | USD 14.21 0.03 0.21% |
Slightly above 57% of Syndax Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Syndax Pharmaceuticals suggests that many traders are alarmed. Syndax Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Syndax Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Syndax |
Incyte and Syndax Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Niktimvo in 9 mg and 22 mg vial sizes. The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg . Nik
Read at finance.yahoo.com
Syndax Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
43
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Syndax Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Syndax Pharmaceuticals.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
Syndax Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Syndax Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Syndax Pharmaceuticals Historical Investor Sentiment
Investor biases related to Syndax Pharmaceuticals' public news can be used to forecast risks associated with an investment in Syndax. The trend in average sentiment can be used to explain how an investor holding Syndax can time the market purely based on public headlines and social activities around Syndax Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Syndax Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Syndax Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Syndax Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Syndax Pharmaceuticals.
Syndax Pharmaceuticals Fundamental Analysis
We analyze Syndax Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Syndax Pharmaceuticals is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Syndax Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Syndax Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Syndax Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Syndax Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Syndax Pharmaceuticals Related Equities
MRSN | Mersana Therapeutics | 8.47 | ||||
LRMR | Larimar Therapeutics | 6.61 | ||||
RVMD | Revolution Medicines | 5.25 | ||||
DYN | Dyne Therapeutics | 4.43 | ||||
STRO | Sutro Biopharma | 3.72 | ||||
PCVX | Vaxcyte | 3.70 | ||||
COGT | Cogent Biosciences | 3.44 | ||||
VRDN | Viridian Therapeutics | 3.35 | ||||
KROS | Keros Therapeutics | 2.99 | ||||
INZY | Inozyme Pharma | 2.82 | ||||
CYTK | Cytokinetics | 2.71 | ||||
AVTE | Aerovate Therapeutics | 1.55 | ||||
MRUS | Merus BV | 0.19 | ||||
PLRX | Pliant Therapeutics | 0.74 | ||||
MLYS | Mineralys Therapeutics, | 0.87 | ||||
KALV | Kalvista Pharmaceuticals | 1.13 | ||||
EWTX | Edgewise Therapeutics | 1.48 | ||||
CGEM | Cullinan Oncology | 2.40 | ||||
REPL | Replimune | 3.20 |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.